Trial Profile
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2021
Price :
$35
*
At a glance
- Drugs Clesacostat (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Oct 2021 Results of two studies (NCT03248882 & NCT03776175) assessing the effects of PF-05221304 (15 mg twice daily (BID)) co-administered with a DGAT2 inhibitor, PF-06865571 (300 mg BID), versus placebo after 6 weeks of treatment, published in the Nature Medicine.
- 09 May 2019 Status changed from active, no longer recruiting to completed.
- 20 Apr 2019 Planned End Date changed from 8 Apr 2019 to 1 Apr 2019.